GlobeNewswire by notified

Solvay nine months 2021 results

Share

Register to the webcast scheduled at 13:00 CEST here - Link to financial report - Link to financial calendar

Solvay nine months 2021 results
Strong profit due to high demand, price and mitigation actions overcoming significant inflationary pressure

Highlights

  • Net sales in the third quarter of 2021 were up +25% organically versus Q3 2020 and up by +6% organically compared to Q3 2019 (+12% excluding Composites), reflecting continued strong demand in most of our markets including record sales in Specialty Polymers. Nine months 2021 sales were 15% organically above 9M 2020, and up +0.5% (+6% excluding Composites) compared to 2019.
  • Underlying EBITDA at €599 million in Q3 2021 was up +31% year on year on a comparable scope and foreign exchange basis, reflecting demand recovery, mitigating actions in the face of sharp increases in energy prices, raw materials and logistics, and structural cost savings of €41 million. Nine months 2021 EBITDA is 28% higher than in 2020 and is 6% higher compared to 2019 (at constant scope and currency).
  • EBITDA margin at 23.3% is 0.8 percentage points higher than Q3 2020 thanks to higher volumes, pricing, and structural cost measures which partially offset the €145 million impact from rising raw materials, energy and logistics costs.
  • Underlying Net Profit at €273 million in Q3 2021, 55% higher than versus Q3 2020.
  • Free Cash Flow1 amounted to €276 million in Q3 2021, marking the 10th consecutive quarter of positive free cash flow and bringing the nine months 2021 total to €692 million.
  • Interim dividend of €1.50 gross per share decided by the Board of Directors, stable year on year, to be paid on January 17, 2022.
  • Solvay ONE Planet sustainability roadmap strengthened with new commitment to reach carbon neutrality before 2050.
Third quarter Nine months
Underlying (in € million) 202120202019% org 21/20% org
21/19
202120202019% org
21/20
% org
21/19
Net sales2,5732,1032,578+24.7%+6.2%7,4026,7517,803+15.1%+0.5%
EBITDA599473601+31.1%+6.7%1,7841,4811,796+28.0%+5.7%
EBITDA margin23.3%22.5%23.3%--24.1%21.9%23.0%--
FCF 1276366313--692801345--
FCF conversion ratio (LTM)39.5%54.8%35.3%--39.5%54.8%35.3%--

CEO Quote
“I want to thank our teams for another strong set of results. We saw continued demand recovery in most of our businesses and achieved record sales in Specialty Polymers. Indeed, our Q3 sales performance represents high single-digit growth versus 2019 despite slower dynamics in civil aerospace. Our relentless focus on cost and price actions allowed margins to remain stable comparatively to their pre-covid19 level. Looking forward, further actions are being implemented to account for the rising raw materials, energy and logistics costs. Despite these macro headwinds, we maintain our EBITDA guidance and upgrade our Free Cash Flow estimate by €50 million. As we execute on our GROW strategy, we continue to disproportionately allocate resources to our growth businesses and platforms in order to further enhance our capacity to generate superior and sustainable growth for the future.

I am also proud to announce today that Solvay has targeted carbon neutrality before 2050. We remain focused on delivering on our Solvay One Planet priorities and we will raise the bar in response to climate change. Today’s announcement represents a key step forward in our journey toward net-zero emissions.”

20212 Outlook

Full year underlying EBITDA estimate is maintained in the range of €2.2 to €2.3 billion notwithstanding the expectation that high energy prices will persist into Q4 2021. The free cash flow estimate is upgraded to around €800 million.


1 Free cash flow is free cash flow to Solvay shareholders from continuing operations
2 Barring additional deterioration related to another wave of Covid-19 in the fourth quarter.


Safe harbor
This press release may contain forward-looking information. Forward-looking statements describe expectations, plans, strategies, goals, future events or intentions. The achievement of forward-looking statements contained in this press release is subject to risks and uncertainties relating to a number of factors, including general economic factors, interest rate and foreign currency exchange rate fluctuations, changing market conditions, product competition, the nature of product development, impact of acquisitions and divestitures, restructurings, products withdrawals, regulatory approval processes, all-in scenario of R&I projects and other unusual items. Consequently, actual results or future events may differ materially from those expressed or implied by such forward-looking statements. Should known or unknown risks or uncertainties materialize, or should our assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors23.4.2024 19:42:34 CEST | Press release

Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare cancer that is often unresectable and commonly diagnosed in the late stages of disease Novartis, a leader in radioligand therapy (RLT), is investigating a portfolio of RLTs to treat a broad range of cancers, including GEP-NETs, lung, prostate, breast, colon, brain and pancreatic cancers Basel, April 23, 2024 – Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Lutathera® (USAN: lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for the treatment of pediatric patients 12 years and older with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut NETs. This approval makes Lutathera the first therapy specifically reviewed and appro

Grant of warrants23.4.2024 19:20:21 CEST | Press release

23 April 2024 Announcement no. 9 Grant of Warrants COPENHAGEN, DENMARK and BOSTON, MA, USA, April 23, 2024 (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has resolved, in accordance with the annual general meeting’s resolution on April 27, 2023, to issue a total of 4,000,000 warrants to members of the Executive Management. Each warrant grants the holder the right to subscribe for one share in BioPorto. The exercise price is DKK 1.23 per share, corresponding to the closing price today on Nasdaq Copenhagen. The warrants are issued in accordance with section 18 a of the Articles of Association. Half of the warrants vest over a 2-year period, and the remaining half upon completion of a qualified capital raise in the Company with terms of qualification (including timing and amount of proceeds) to be defined by the Board of Directors. The warrants are otherwise subject to the Company’s incentive warrant program as included in Appendix 1 o

TrueCommerce leverer globale e-fakturerings- og CTC-løsninger til virksomheder, der har udfordringer med overholdelse23.4.2024 19:10:28 CEST | pressemeddelelse

Virksomheden er ene om at tilbyde en global løsning, der omfatter e-fakturering, CTC-løsninger og et omfattende EDI-netværk, alt sammen problemfritintegreret med B2B e-handels- og ERP-systemer KØBENHAVN, Danmark, April 23, 2024 (GLOBE NEWSWIRE) -- TrueCommerce, en global leverandør af forsyningskæde- og handelspartnerforbindelser, integration og løsninger via flere kanaler, har i dag givet meddelelse om sin globale løsning til e-fakturering og Continuous Transaction Controls (CTC), der gør det muligt for organisationer at holde trit med de konstant skiftende juridiske krav overalt i verden og understøtter elektronisk fakturering, som opfylder de gældende krav. TrueCommerce er en global markedsaktør, der understøtter både e-fakturering og CTC og giver adgang til et omfattende globalt EDI-netværk samt B2B e-handel og ERP-integration. På grund af kompleksiteten i at navigere i et landskab af stadigt skiftende landespecifikke e-faktureringskrav og deadlines, står virksomheder over for en s

Festi hf.: Financial results for Q1 202423.4.2024 19:02:17 CEST | Press release

Key findings Sale of goods amounted to ISK 32,223 million, compared to ISK 29,484 million in the previous year, an increase of 9.3% between years.Gross profit from sales of goods and services amounted to ISK 7,033 million, an increase of 806 million or 12.9% between years.Profit Margins from sales of goods and services were 21.8% and increases by 0.7 p.p. from Q1 2023 but decreases by 1.2 p.p. from Q4 2023.Salaries and other personnel expenses increase by 7.5% and full-time equivalents by 2.5%.EBITDA amounted to ISK 1,898 million compared to ISK 1,401 million in Q1 2023, increase of 35.5% between years. Profit for the quarter amounted to ISK 202 million, or 2.9% of margin, a turnaround of ISK 293 million YoY.Net cash from operating activities was ISK 538 million or 7.6% of margin, compared to ISK 1,238 million last year.Equity at the end of Q1 2024 amounted to ISK 35,140 million with an equity ratio of 36.0%. EBITDA forecast for the year 2024 is raised by ISK 300 million and is now ISK

ASM reports first quarter 202423.4.2024 18:00:00 CEST | Press release

Almere, The Netherlands April 23, 2024, 6 p.m. CET Solid start of the year, Q1 orders supported by GAA and HBM ASM International N.V. (Euronext Amsterdam: ASM) today reports its Q1 2024 results (unaudited). Financial highlights € millionQ1 2023Q4 2023Q1 2024 New orders 647.4 677.5 697.9 yoy change % at constant currencies (6%) (14%) 10% Revenue 710.0 632.9 639.0 yoy change % at constant currencies 40% (7%) (8%) Gross profit margin % 49.4 % 47.2 % 52.9 % Adjusted gross profit margin 1 51.1 % 47.9 % 52.9 % Operating result 204.2 131.5 187.1 Operating result margin % 28.8 % 20.8 % 29.3 % Adjusted operating result 1 221.2 141.0 191.8 Adjusted operating result margin 1 31.2 % 22.3 % 30.0 % Net earnings 380.4 90.9 173.1 Adjusted net earnings 1 183.0 100.3 178.9 1 Adjusted figures are non-IFRS performance measures (previously referred to as "normalized"). Refer to Annex 3 for a reconciliation of non-IFRS performance measures. New orders of €698 million in Q1 2024 increased by 10% at constant

HiddenA line styled icon from Orion Icon Library.Eye